Lipozene is a capsule of konjac fibre sold as a dietary supplement, and its strongest marketing claim rests on a subgroup. Its one active ingredient is glucomannan, the same fibre whose trial record is set out on our glucomannan page. What is particular to Lipozene is the brand's own label and claims, the trial its website describes, and a legal record that runs from a 2005 FTC order to a 2019 class settlement. This page reports all three, dated, and says what is not established.
Read on 16 November 2026 from lipozene.com, the NIH Dietary Supplement Label Database, PubMed, the FTC's 2005 release and published accounts of the class actions.
What the label says
The NIH Dietary Supplement Label Database holds three Lipozene labels from Obesity Research Institute, all listed as on the market. The 2019 label, "Maximum Strength Lipozene", states:
| Label item | What it says |
|---|---|
| Statement of identity | Dietary supplement |
| Active ingredient | "Proprietary Blend", 1,500 mg per serving; contains Amorphophallus konjac |
| Serving | 2 capsules; 30 capsules = 15 servings |
| Directions (label wording, condensed) | 2 capsules, 30 minutes before meals, "up to three times per day with at least 8 oz. of water" |
| Warnings | Taking it without adequate fluid "may cause it to swell and block your throat or esophagus and may cause choking"; do not use if pregnant or lactating; do not use with difficulty swallowing |
| Claims printed | "Clinically proven: Helps reduce weight, Helps reduce body fat, Safe & effective" |
| Terms | Sales subject to terms that include "a mandatory, binding arbitration clause and a waiver of the right to a jury trial or to participate in a class action" |
At the label's maximum directions, three servings a day come to 4.5 g of glucomannan. The one weight claim the EU authorises for glucomannan was set at 3 g a day, as part of an energy-restricted diet; that condition and its choking warning are on the glucomannan page.
The website calls Lipozene "America's #1 diet supplement". Its footnote narrows that to "the number one selling fiber supplement based on single SKU IRI sales data from June 2013 to June 2024". It also describes the formula as stimulant-free and caffeine-free. That applies to Lipozene alone: two of the three packs on sale include MetaboUP PLUS, whose listed ingredients include kola nut and guarana seed, both plant sources of caffeine, beside green tea and oolong tea leaf.
What the maker's trial claim says, and what the trial found
The site's claim, in its own footnote: "ORI sponsored an 8-week study where participants were instructed to take Amorphophallus konjac (glucomannan) … but were not given instruction as to diet or exercise. On average, the compliant active subgroup lost 4.93 more pounds than the placebo group … It was shown to be 4x more effective than a placebo."
The website does not name a paper. The published trial that fits its description is Kaats, Bagchi and Preuss, J Am Coll Nutr 2015: 83 overweight adults (66 women, 17 men) completed 60 days on either a supplement containing 3 g of konjac glucomannan with 300 mg of calcium carbonate or a placebo of calcium carbonate alone, with body scans and blood tests at the start and end. Its abstract reports:
- The main comparison found nothing. "No statistically significant differences were found between the groups on changes from baseline on the DEXA and blood tests."
- The effect appeared only after a re-grouping. Participants were sorted into "compliant" and "partially compliant" from their own reports of how many tablets they took and whether they took them 30 minutes before eating. Within those groups, the glucomannan arm showed significant falls in weight, body fat and cholesterol.
- The authors say so themselves: "these positive outcomes were not observable until corrections for compliance were applied."
The abstract gives no pound figure, so whether the website's 4.93 lb and "4x" come from this paper cannot be confirmed from it. What the abstract does show is the general point: a result from a subgroup chosen after the fact, on self-reported adherence, is weaker evidence than the trial's main comparison, and here the main comparison was null. The independent reviews of glucomannan trials, which do not rest on any one maker's study, put the effect over placebo between −0.22 kg (not significant) and −1.27 kg; the one that set a threshold for clinical significance, 2.5 kg, found glucomannan below it.
The legal record
The 2005 FTC order. On 20 June 2005 the FTC announced a settlement with FiberThin, LLC, Obesity Research Institute, LLC, their owners and two endorsers, filed in federal court in the Southern District of California. The products were two fibre supplements, FiberThin and Propolene, marketed with two "metabolism enhancers", one of them named MetaboUp. The FTC challenged claims of rapid weight loss of more than 2 pounds a week "without the need to diet or exercise", weight loss whatever the buyer ate, and weight loss in all users. The order prohibits those claims, prohibits unsubstantiated claims for any weight-loss product, food, drug or supplement, and prohibits misrepresenting any scientific study. The companies and owners were to pay $1.5 million in consumer redress, with a $41 million suspended judgment. The release notes the settlement was not an admission of a violation.
The 2016 complaint to the FTC. On 7 April 2016 the advertising watchdog Truth in Advertising sent the FTC a complaint saying Lipozene ads claimed substantial weight loss without changes in diet or exercise, in breach of the 2005 order, and urging the agency to reopen its investigation. No FTC action following that letter was found in the records read for this page.
The class actions. Bozic v. Obesity Research Institute (S.D. Cal., No. 16-cv-733), filed in March 2016, alleged Lipozene was falsely advertised as clinically proven to cause weight loss without exercise or diet change; in January 2017 it was transferred to be consolidated with Fernandez v. Obesity Research Institute. Fernandez settled in 2019 for $4.6 million for buyers between 10 August 2012 and 28 October 2019: $15 a bottle for up to four bottles with proof of purchase, or $7 for one without. The plaintiffs alleged, among other things, that glucomannan is not absorbed by the body. The defendants denied all the allegations and agreed to stop using two advertising lines: "Lipozene is so powerful …" and "Lipozene is specifically designed to target fat."
What it costs, as the maker lists it
| Pack on lipozene.com, 16 November 2026 | Price |
|---|---|
| Starter plan: 2 × 30 capsules Lipozene + 1 × 30 MetaboUP PLUS | $29.95 |
| Results pack: 2 × 120 capsules Lipozene (60 days) | $54.95 |
| Best value: 3 × 120 capsules Lipozene + 3 × 60 MetaboUP PLUS (90 days) | $89.95 |
The site's FAQ says purchases made directly come with a 30-day money-back guarantee "excluding a $1.35 processing fee", and its footer says the guarantee "applies only to the first 30 days of a continuity subscription" and does not cover later deliveries. Phone orders on a subscription are cancelled by phone, not online. Retail prices differ and were not read.
Where it sits beside prescription medicines
Lipozene contains no medicine. The prescription drugs approved for long-term weight management, and the one over-the-counter drug, orlistat 60 mg, are listed on our register of weight-loss pills; the injected options are on weight-loss injections. For scale, with populations named: in adults with obesity and no diabetes, semaglutide 2.4 mg lowered weight by 14.9% against 2.4% on placebo over 68 weeks (STEP 1) and tirzepatide 15 mg by 20.9% against 3.1% over 72 weeks (SURMOUNT-1). No trial has compared Lipozene or glucomannan with either, and kilograms over weeks are not the same measure as percentage of body weight over more than a year. Other fibre and "booster" products are on GLP-1 supplements.
What is not established
- No trial of Lipozene as a branded product is published; the trial that matches the maker's description tested glucomannan tablets and was null on its main comparison.
- Whether the website's 4.93 lb and "4x" figures come from that paper is not shown in its abstract.
- No long-term trial of glucomannan exists, so nothing shows whether any effect lasts beyond a few months.
- The FTC's response, if any, to the 2016 complaint is not on the public record read for this page.
A pharmacist or doctor is the right person to ask before starting it, particularly for anyone with a swallowing problem, a bowel condition, a heart condition (the bundled MetaboUP PLUS contains caffeine sources) or on other medicines, since a swelling fibre can change when tablets are absorbed. This page reports the record; it does not recommend Lipozene or any other product.
Sources
- NIH Office of Dietary Supplements, Dietary Supplement Label Database: Maximum Strength Lipozene, labels 206402 (2019), 33165 (2014), 6059 (2012); MetaboUP Plus, label 206478 — read 16 November 2026.
- lipozene.com — home page, FAQs and ingredients pages, read 16 November 2026.
- Kaats GR, Bagchi D, Preuss HG. Konjac glucomannan dietary supplementation causes significant fat loss in compliant overweight adults. J Am Coll Nutr 2015, PMID 26492494, doi:10.1080/07315724.2015.1009194 (abstract read).
- FTC, "FTC Settles Claims with Marketers of FiberThin and Propolene", 20 June 2005 — ftc.gov, read 16 November 2026.
- Truth in Advertising, Lipozene brand file and class-action tracker (Bozic, No. 16-cv-733, S.D. Cal.), read 16 November 2026.
- Manatt, Phelps & Phillips, "Weight Loss Supplement Class Gains $4.6M Settlement", 11 December 2019 (Fernandez v. Obesity Research Institute).
- Glucomannan reviews and GLP-1 trials as cited on our glucomannan page: Onakpoya 2014 (PMID 24533610), Bessell 2021 (PMID 33976376); Wilding 2021 (PMID 33567185); Jastreboff 2022 (PMID 35658024).
